Key result
Tacrolimus administered during early reperfusion significantly reduced myocardial infarct size and histopathological damage compared to control in a rat model.
Why the study?
Reperfusion can induce cardiomyocyte death known as myocardial reperfusion injury, and tacrolimus has diverse actions that ameliorate ischemia/reperfusion injury beyond immunosuppression.
Does tacrolimus reduce infarct size and myocardial ischemia/reperfusion injury in a rat model?
Does tacrolimus reduce infarct size and myocardial ischemia/reperfusion injury in a rat model?
p-value: p=<0.05
Tacrolimus administered during early reperfusion significantly reduces infarct size and attenuates histopathological damage in a rat model of myocardial ischemia/reperfusion injury.
Should not yet change practice; hypothesis-generating for tacrolimus in myocardial reperfusion injury.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
ÇOMAKLI et al. (2021) studied Myocardial ischemia/reperfusion injury (n=18). Tacrolimus vs. Saline was evaluated on Infarct size (p=<0.05). Tacrolimus administered during early reperfusion significantly reduced myocardial infarct size and histopathological damage compared to control in a rat model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: